Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-high trading volume on Thursday . Approximately 1,542,775 shares changed hands during trading, an increase of 690% from the previous session’s volume of 195,207 shares.The stock last traded at $27.00 and had previously closed at $26.35.

Analyst Ratings Changes

A number of brokerages have issued reports on DNTH. Wedbush dropped their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Raymond James raised their price objective on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

The company has a market cap of $808.89 million, a price-to-earnings ratio of -10.54 and a beta of 1.84. The stock’s fifty day simple moving average is $27.70 and its two-hundred day simple moving average is $26.64.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC lifted its holdings in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $265,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $334,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.